A step-by-step guide to developing a robust assay in bioanalysis using LC-MS/MS

Blog - Read our guide ‘A step-by-step guide to developing a robust assay in bioanalysis using LC-MS/MS’ to learn about our proven approach to developing industry-leading LC-MS/MS bioassays.

22 September 2022
Cocrystal - Motivation and Theory - Solid Form Screening

Blog - Sponsors may require a cocrystal screen for a number of reasons, or a combination of these, dissolution rate/solubility, crystallinity, novelty, hydration issues, other processability and stability.

21 September 2022
Crystallisation and Screening Theory - Solid Form Screening

Blog - Crystals are distinguished from amorphous solids by possessing both short and long range regular structure, minimal repeating units within this matrix are termed unit cells.

15 September 2022
Salt Screening - Motivation and Theory - Solid Form Screening

Blog - Sponsors may require a salt screen for a number of reasons, or a combination of these: Solubility, Stability, Crystallinity, Novelty, Other processability.

14 September 2022
What makes a good LC-MS/MS bioassay?

Blog - What makes a good LC-MS/MS bioassay? When selecting your LC-MS/MS method approach it is worth doing your homework. Pick an assay format that is best suited to your compound and consider factors such as matrix type, analyte structure, choice and availability of reagents, and the sensitivity and specificity you need.

01 September 2022
Polymorph Screening - Motivation and Theory - Solid Form Screening

Blog - It is unusual for a sponsor to require a polymorph screen before investigating salts and cocrystals first. All crystalline materials, whether parent API, salt or cocrystal may exist in multiple polymorphic forms usually identified by the Roman numerals I, II, III, IV etc.

12 August 2022
A method to measure anti-vaccine antibodies

Blog - An antibody assay was required to detect and quantify IgGs produced against a vaccine. This was required to measure the efficacy and reliability of the vaccine.

15 July 2022
Challenges of developing an ADA assay for bispecific antibody therapeutics and ADA characterisation

Blog - Bispecifics (Bs) are biopharmaceutical products that bind to two different targets (epitopes). These are mainly two types: IgG-like (antibodies Abs) and non-IgG-like which include Bites (bispecific T-cell engager) and DARTs (Dual-affinity Re-targeting Antibody).

24 May 2022
Introduction to Pharmacokinetics

Blog - An understanding of the characteristics of drug exposure following administration and how it relates to safety and efficacy is critical for progressing drug development (e.g. in decision making for drug candidates, design of dosing regimens and making predictions for future studies) as well as being a requirement for regulatory authorities. Pharmacokinetics (PK) analysis aims to evaluate quantitatively how a drug enters the body, what happens to the drug while in the body and ultimately, how it is removed. These processes are commonly referred to by the acronym ‘ADME’, which comprises absorption, distribution, metabolism and excretion.

07 January 2022
Pharmacokinetics (PK) urine analysis

Blog - Urinary pharmacokinetics (PK) parameters tell you about how much drug was absorbed and how much drug is eliminated

03 January 2022